Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.

Abstract

UNLABELLED:

Anti-oxidant interventions consist in reduction of direct oxidant damage by removing oxidant agents and/or by supplementing reducing agents with anti-oxidant effects.

AIM:

Aim of the present study was to investigate the anti-oxidant effects of erdosteine, a recent drug currently used in chronic obstructive pulmonary disease (COPD) for its rheological activity. At present, no data are available on current smokers with COPD to our knowledge.

METHODS:

Two groups of 10 persons matched for sex; age (65.0 yr+/-8.4 S.D. and 65.3 yr+/-6.5 S.D.); basal FEV1 (88.7% pred +/-6.8 S.D. and 85.2% pred +/-5.8 S.D.); and cigarette consumption (25.4 pack/yr+/-3.5 S.D. and 28.1 pack/yr+/-2.3 S.D.) entered a controlled, double blind, parallel groups study. They were randomized to receive erdosteine 600 mg daily or placebo for 10 days. IL-6; IL-8; TNFalpha were measured in bronchial secretions in bsln, after 4, 7, and 10 days of Erdosteine or placebo; e-NO and both ROS and 8-Isoprostane in blood were also measured at the same experimental times.

STATISTICS:

ANOVA: a t-test with Bonferroni correction; p<0.05 was accepted.

RESULTS:

Blood ROS and IL-8 in bronchial secretions dropped significantly following erdosteine starting from day 4 (both p<0.01), while 8-isoprostane drop was significant only after day 10 (p<0.02), and the e-NO decrease proved evident but not significant. No significant changes were observed in the placebo group.

CONCLUSIONS:

Erdosteine affects substantially some pro-inflammatory cytokines specifically involved in oxidative stress in current smokers with mild COPD. Effects appeared differently time-dependent. Further long-term studies are needed to confirm these pilot data and to assess their long-term clinical relevance.

• Authors: R W Dal Negro, M Visconti, C Micheletto, S Tognella
• Journal: Pulmonary pharmacology & therapeutics (Pulm Pharmacol Ther) Vol. 21 Issue 2 Pg. 304-8 ( 2008) ISSN: 1094-5539 [Print] England
• PMID: 17889580 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Antioxidants
• Cytokines
• Interleukin-6
• Interleukin-8
• Reactive Oxygen Species
• Thioglycolates
• Thiophenes
• Tumor Necrosis Factor-alpha
• 8-epi-prostaglandin F2alpha
• Nitric Oxide
• erdosteine
• Dinoprost

Topics

• Aged
• Analysis of Variance
• Antioxidants (pharmacology, therapeutic use)
• Breath Tests
• Bronchi (drug effects, metabolism)
• Cytokines (blood, metabolism)
• Dinoprost (analogs & derivatives, blood)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Interleukin-6 (metabolism)
• Interleukin-8 (metabolism)
• Male
• Middle Aged
• Nitric Oxide (blood)
• Pulmonary Disease, Chronic Obstructive (metabolism)
• Reactive Oxygen Species (blood)
• Smoking (metabolism)
• Thioglycolates (pharmacology, therapeutic use)
• Thiophenes (pharmacology, therapeutic use)
• Time Factors
• Tumor Necrosis Factor-alpha (blood)